US FDA Biologics Designation As Price Protection: Lilly Charts New Course With Retatrutide

 
• By Cathy Kelly
  
Lilly is Seeking Biologics Status for its investigational obesity agent. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access